News Articles

Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies Recommended... INCHEON, Korea -Friday 12 November 2021  

 The CHMP positive opinion marks the first time a monoclonal antibody treatment for COVID-19 has received a recommendation for marketing authorisation from the EMA The recommendation is based on data from the global Phase III clinical trial investigating regdanvimab as a treatment for...

 Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized... -Monday 20 September 2021  

 The approval marks the first time a monoclonal antibody treatment for COVID-19 received full approval to treat patients with COVID-19 The approval includes an expansion of patients that can be treated with regdanvimab (CT-P59) for COVID-19 and a reduced time period for the treatment...

Celltrion’s Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising... -Monday 19 July 2021  

(BUSINESS WIRE) -- Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab (CT-P59) has a strong neutralising effect against the rapidly spreading Delta variant (B.1.617.2, first identified in India). According to the World Health Organization...